ARQT - Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

• Arcutis Biotherapeutics ( NASDAQ: ARQT ) said that top-line phase 3 results for roflumilast foam in scalp and body psoriasis met their co-primary endpoints .
• Results showed that at week 8, 67.3% of patients treated with roflumilast, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, achieved S-IGA Success compared to 28.1% of those treated with a matching vehicle foam. For B-IGA success, the figures were, respectively, 46.5% and 20.8%.
• Roflumilast also led to statistically significant improvements in secondary endpoints, including scalp itch and overall itch at week 8.
• Arcutis ( ARQT ) previously said it planned to submit an NDA for roflumilast in Q1 2023.
• Check out Seeking Alpha contributor's Bret Jensen's bullish assessment of Arcutis ( ARQT ).

For further details see: